ArticleMolecular oncology2017

Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.

Peng Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.